国际中医中药杂志
國際中醫中藥雜誌
국제중의중약잡지
INTERNATIONAL JOURNAL OF TRIDITIONAL CHINESE MEDICINE
2014年
7期
607-609
,共3页
股骨头坏死%中医药分期治疗%疗效分析
股骨頭壞死%中醫藥分期治療%療效分析
고골두배사%중의약분기치료%료효분석
Osteonecrosis of femoral head%Treatment by stage%Therapeutic evaluation
目的：探讨中药自拟方治疗分期治疗股骨头坏死（osteonecrosis of the femoral head，ONFH）的临床疗效。方法收集2010年7月至2013年7月本院骨科住院早、中期ONFH患者106例，采用随机数字表法将患者随机分为两组各53例，治疗组患者早期服用自拟健脾活血方，中期服用自拟补肾活血方治疗；对照组口服仙灵骨葆胶囊与洛伐他汀胶囊治疗。两组均治疗6周为1个疗程，治疗2个疗程后评价临床疗效和血液流变学指标。结果治疗后治疗组总有效率为90.6%（48/53），对照组为73.6%（39/53），两组总有效率比较，差异有统计学意义（χ2＝6.731，P＜0.05）。治疗后治疗组全血黏度高切、中切、低切，血浆黏度（PV）、红细胞压积（HCT）、红细胞聚集指数（Arbe）、红细胞沉降率（ESR）、纤维蛋白原（FIB）[(3.42±0.72)mPa?S、(4.21±0.30)mPa?S、(8.36±0.12)mPa?S、(1.39±0.16)mPa?S、(38.34±2.37)%、(5.47±0.33)、(27.35±2.16)mm/h、(3.83±0.47)g/L]均较同组治疗前[(3.97±0.21)mPa?S、(4.71±0.24)mPa?S、(9.58±0.31)mPa?S、(2.01±0.13)mPa?S、(41.29±1.01)%、(6.51±0.21)、(14.62±0.92)mm/h、(4.94±0.26)g/L]明显改善（ P＜0.05）；且治疗组各检测指标与对照组[(3.76±0.08)mPa?S、(4.47±0.16)mPa?S、(8.99±0.07)mPa?S 、(1.72±0.14)mPa?S 、(40.46±1.06)%、(6.11±0.38)、(24.98±1.42)mm/h 、(4.33±0.57)g/L]比较，差异均有统计学意义（P＜0.01或0.05）。结论中药自拟方分期治疗可改善ONFH患者血液流变学指标，提高骨密度，促进骨小梁生长。
目的：探討中藥自擬方治療分期治療股骨頭壞死（osteonecrosis of the femoral head，ONFH）的臨床療效。方法收集2010年7月至2013年7月本院骨科住院早、中期ONFH患者106例，採用隨機數字錶法將患者隨機分為兩組各53例，治療組患者早期服用自擬健脾活血方，中期服用自擬補腎活血方治療；對照組口服仙靈骨葆膠囊與洛伐他汀膠囊治療。兩組均治療6週為1箇療程，治療2箇療程後評價臨床療效和血液流變學指標。結果治療後治療組總有效率為90.6%（48/53），對照組為73.6%（39/53），兩組總有效率比較，差異有統計學意義（χ2＝6.731，P＜0.05）。治療後治療組全血黏度高切、中切、低切，血漿黏度（PV）、紅細胞壓積（HCT）、紅細胞聚集指數（Arbe）、紅細胞沉降率（ESR）、纖維蛋白原（FIB）[(3.42±0.72)mPa?S、(4.21±0.30)mPa?S、(8.36±0.12)mPa?S、(1.39±0.16)mPa?S、(38.34±2.37)%、(5.47±0.33)、(27.35±2.16)mm/h、(3.83±0.47)g/L]均較同組治療前[(3.97±0.21)mPa?S、(4.71±0.24)mPa?S、(9.58±0.31)mPa?S、(2.01±0.13)mPa?S、(41.29±1.01)%、(6.51±0.21)、(14.62±0.92)mm/h、(4.94±0.26)g/L]明顯改善（ P＜0.05）；且治療組各檢測指標與對照組[(3.76±0.08)mPa?S、(4.47±0.16)mPa?S、(8.99±0.07)mPa?S 、(1.72±0.14)mPa?S 、(40.46±1.06)%、(6.11±0.38)、(24.98±1.42)mm/h 、(4.33±0.57)g/L]比較，差異均有統計學意義（P＜0.01或0.05）。結論中藥自擬方分期治療可改善ONFH患者血液流變學指標，提高骨密度，促進骨小樑生長。
목적：탐토중약자의방치료분기치료고골두배사（osteonecrosis of the femoral head，ONFH）적림상료효。방법수집2010년7월지2013년7월본원골과주원조、중기ONFH환자106례，채용수궤수자표법장환자수궤분위량조각53례，치료조환자조기복용자의건비활혈방，중기복용자의보신활혈방치료；대조조구복선령골보효낭여락벌타정효낭치료。량조균치료6주위1개료정，치료2개료정후평개림상료효화혈액류변학지표。결과치료후치료조총유효솔위90.6%（48/53），대조조위73.6%（39/53），량조총유효솔비교，차이유통계학의의（χ2＝6.731，P＜0.05）。치료후치료조전혈점도고절、중절、저절，혈장점도（PV）、홍세포압적（HCT）、홍세포취집지수（Arbe）、홍세포침강솔（ESR）、섬유단백원（FIB）[(3.42±0.72)mPa?S、(4.21±0.30)mPa?S、(8.36±0.12)mPa?S、(1.39±0.16)mPa?S、(38.34±2.37)%、(5.47±0.33)、(27.35±2.16)mm/h、(3.83±0.47)g/L]균교동조치료전[(3.97±0.21)mPa?S、(4.71±0.24)mPa?S、(9.58±0.31)mPa?S、(2.01±0.13)mPa?S、(41.29±1.01)%、(6.51±0.21)、(14.62±0.92)mm/h、(4.94±0.26)g/L]명현개선（ P＜0.05）；차치료조각검측지표여대조조[(3.76±0.08)mPa?S、(4.47±0.16)mPa?S、(8.99±0.07)mPa?S 、(1.72±0.14)mPa?S 、(40.46±1.06)%、(6.11±0.38)、(24.98±1.42)mm/h 、(4.33±0.57)g/L]비교，차이균유통계학의의（P＜0.01혹0.05）。결론중약자의방분기치료가개선ONFH환자혈액류변학지표，제고골밀도，촉진골소량생장。
Objective To explore the clinical effects of treating osteonecrosis of femoral head(ONFH) by stages with self designed Chinese medicine formula. Methods 106 ONFH patients in Shantou municipal TCM hospital from July 2010 to July 2013 were recruited and divided randomly into a control group and a treatment group, 53 patients in each. The treatment group was treated with self-designed Chinese medicine formula with the functions of strengthening spleen and promoting blood circulation in the early stage, and self-designed Chinese medicine formula with the functions of supplementing kidney and promoting blood circulation in the middle stage of disease, one dosage daily. The control group was treated with Xianliang Gubao capsule (3 granules per time, twice daily) and lovastatin capsule (10-20 mg per time). Both groups were treated for two therapeutic courses of 8-12 weeks. X-ray and hemorheology indexes were observed after the treatment. Results The total effects was 90.6%(48/53) and 73.6%(39/53) in the treatment group and the control group respectively, with significant difference(χ2=6.731,P<0.05);Whole blood viscosity, PV, HCT, Arbe, ESR, FIB were obviously improved in the treatment group after the treatment, [after the treatment: whole blood viscosity high cut(3.42±0.72)mPa?S, middle cut(4.21±0.30)mPa?S, low cut(8.36±0.12)mPa?S, PV(1.39±0.16)mPa?S, HCT(38.34±2.37)%, Arbe(5.47±0.33), ESR(27.35±2.16)mm/h, FIB(3.83±0.47)g/L], [before the treatment:whole blood viscosity high cut(3.97±0.21)mPa?S, middle cut (4.71±0.24)mPa?S, low cut (9.58±0.31)mPa?S, PV(2.01±0.13)mPa?S, HCT(41.29±1.01)%, Arbe(6.51±0.21),ESR(14.62±0.92)mm/h, FIB(4.94±0.26)g/L, P<0.05]. After the treatment, the treatment group was obviously improved in such indexes as whole blood viscosity high cut(3.76±0.08)mPa?S, middle cut(4.47±0.16)mPa?S, low cut (8.99±0.07)mPa?S, PV(1.72±0.14)mPa?S, HCT(40.46±1.06)%, Arbe(6.11±0.38), ESR(24.98±1.42)mm/h and FIB(4.33±0.57)g/L than the control group(P<0.01 or 0.05). Conclusion Self-designed Chinese medicine formula stage-therapy had better results in treating ONFH than Xianling Gubao capsule and lovastatin.
